Related Experiment Videos
Immunotherapy for non-Hodgkin's lymphoma
1National Institutes of Health, National Institute on Aging, Baltimore, MD 21224, USA.
Humanized monoclonal anti-CD20 has impressive activity and radioimmunoconjugates. Targeting the same molecule has led to prolonged remissions in both moderate and myeloablative doses. Idiotype-based vaccination has produced an apparent prolongation in disease-free and overall survival in selected patients with follicular lymphoma. Adoptive cellular therapy is active in the setting of Epstein-Barr virus-induced lymphoma after allogenic bone marrow transplantation. Improvements in each of these developments are readily in sight.
Humanized monoclonal anti-CD20 has impressive activity and radioimmunoconjugates. Targeting the same molecule has led to prolonged remissions in both moderate and myeloablative doses. Idiotype-based vaccination has produced an apparent prolongation in disease-free and overall survival in selected patients with follicular lymphoma. Adoptive cellular therapy is active in the setting of Epstein-Barr virus-induced lymphoma after allogenic bone marrow transplantation. Improvements in each of these developments are readily in sight.